

IDS - 12/21/2006

Attorney's Docket No.: 14875-148US1 / C1-A0231P-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Tetsuo Kojima                          Art Unit : 1643  
Serial No. : 10/542,839                          Examiner : Lynn Anne Bristol  
Filed      : December 13, 2005                          Conf. No. : 8994  
Title      : METHODS OF SCREENING FOR ANTIBODY LIGHT CHAINS

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Applicant requests consideration of the references listed on the attached PTO-1449 form.

An English translation of foreign language reference AC is not included, since it is a member of the patent family of English language reference AB.

Applicant wishes to bring to the Examiner's attention co-pending and co-owned non-provisional application serial numbers 10/510,971 (Attorney Docket No. 14875-134US1) and 10/560,098 (Attorney Docket No. 14875-154US1), which concern related subject matter, and some of which have overlapping inventorship with the above-referenced application. Applicant assumes that the Examiner has ongoing access to the files of these related applications and can obtain copies of prosecution documents from the files if at any point in the future she considers it potentially relevant to issues in the present application. Applicant will supply copies of such documents from the related applications' files, should the Examiner request them.

This statement is being filed before the receipt of a first Office Action on the merits.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date:December 21, 2006

/Janis K. Fraser/

Janis K. Fraser, Ph.D., J.D.  
Reg. No. 34,819

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906  
21518638.doc

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. <b>14875-148US1</b>	Application No. <b>10/542,839</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Tetsuo Kojima</b>			
		Filing Date <b>December 13, 2005</b>	Group Art Unit <b>1643</b>		

<b>U.S. Patent Documents</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						

<b>Foreign Patent Documents or Published Foreign Patent Applications</b>								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
LNB	AB	CA 2 331 641	11/11/1999	Canada				
	AC	DE 198 19 846	11/11/1999	Germany			see AB	
	AD	WO 96/34892	11/07/1996	WIPO				
	AE	WO 00/44788	08/03/2000	WIPO				
	AF	WO 01/44282	06/21/2001	WIPO				
↓	AG	WO 01/70775	09/27/2001	WIPO				

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
LNB	AH	De Jonge et al., "Production and Characterization of Bispecific Single-Chain Antibody Fragments," <i>Mol. Immunol.</i> , 32:1405-1412 (1995)
	AI	Hudson et al., "High avidity scFv multimers; diabodies and triabodies," <i>J. Immunol. Methods</i> , 231:177-189 (1999)
	AJ	Kipriyanov et al., "Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies," <i>J. Mol. Biol.</i> , 330:99-111 (2003)
	AK	Krebber et al., "Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system," <i>J. Immunol. Methods</i> , 201:35-55 (1997)
	AL	Kurucz et al., "Retargeting of CTL by an Efficiently Refolded Bispecific Single-Chain Fv Dimer Produced in Bacteria," <i>J. Immunol.</i> , 154:4576-4582 (1995)
	AM	Little et al., "Of mice and men: hybridoma and recombinant antibodies," <i>Immunol. Today</i> , 21:364-370 (2000)
	AN	Peipp et al., "Bispecific antibodies targeting cancer cells," <i>Biochem. Soc. Trans.</i> , 30:507-511 (2002)
	AO	Plückthun et al., "New protein engineering approaches to multivalent and bispecific antibody fragments," <i>Immunotechnology</i> , 3:83-105 (1997)
	AP	Ridgway et al., "'Knobs-into-holes' engineering of antibody C <sub>H</sub> 3 domains for heavy chain heterodimerization," <i>Protein Eng.</i> , 9:617-621 (1996)
	AQ	Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," <i>J. Exp. Med.</i> , 175:217-225 (1992)
↓	AR	Skerra, "Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in <i>Escherichia coli</i> ," <i>Gene</i> , 151:131-135 (1994)

Examiner Signature <i>/Lynn Bristol/</i>	Date Considered <b>02/08/2007</b>
---	--------------------------------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>14875-148US1</b>	Application No. <b>10/542,839</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Tetsuo Kojima</b>	
		Filing Date <b>December 13, 2005</b>	Group Art Unit <b>1643</b>

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>			
Examiner Initial	Desig. ID	Document	
LAB	AS	Völkel et al., "Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies," <i>Protein Eng.</i> , 14:815-823 (2001)	
↓	AT	Zuo et al., "An efficient route to the production of an IgG-like bispecific antibody," <i>Protein Eng.</i> , 13:361-367 (2000)	

Examiner Signature <b>/Lynn Bristol/</b>	Date Considered <b>02/08/2007</b>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modifed) Information Disclosure Statement by Applicant APR 14 2006 (use several sheets if necessary) 7 CFR §1.98(b)(D)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-148US1	Application No. 10/542,839
		Applicant Tetsuo Kojima	
		Filing Date December 13, 2005	Group Art Unit

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
ANB	AJ	WO 98/50431	11/12/1998	WIPO				
	AK	WO 03/087163	10/23/2003	WIPO			X	
	AL	JP 2001-523971	11/27/2001	Japan				X
↓	AM	EP 0774511	5/21/1997	Europe				
	AN							
	AO							

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
ANB	AP	Carter, "Bispecific human IgG by design," J. Immunol. Methods, 248:7-15 (2001)
↓	AQ	Hoogenboom et al., "Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains," Nucleic Acids Res., 19:4133-7 (1991)
↓	AR	Merchant et al., "An efficient route to human bispecific IgG," Nat. Biotechnol., 16:677-81 (1998)
	AS	
	AT	

Examiner Signature <i>/Lynn Bristol/</i>	Date Considered 02/08/2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	